Discovery Provides Hope for New Vaccine Against Flesh-eating Bacteria
News Sep 19, 2017 | Original story from Houston Methodist
Researchers at Houston Methodist have solved a 100-year-old mystery, providing them a possible key to unlock a pathway for treating diseases caused by flesh-eating bacteria. This is timely news, given the current dangers lurking in the debris and destruction left behind by Hurricane Harvey's floodwaters that destroyed tens of thousands of homes in Texas.
Muthiah Kumaraswami, Ph.D., an infectious diseases researcher at the Houston Methodist Research Institute, is the corresponding author and principal investigator on an article describing his team's findings. The paper will appear the week of Sept. 18 in the early edition of the Proceedings of the National Academy of Sciences (PNAS), one of the world's most cited and comprehensive multidisciplinary scientific journals.
"Group A streptococcus infections are pretty widespread. Not only do they cause several million cases of strep throat every year, but also can lead to more severe infections, such as flesh-eating disease and acute rheumatic heart disease," Kumaraswami said. "If you don't treat strep throat in children, for instance, recurring infections can lead to those more serious diseases and are very difficult to treat. We don't have a vaccine, so basic research is geared toward finding targets for vaccine development."
In this paper, Kumaraswami said he and his team found a critical target on which to focus for developing a potential Group A Streptococcus vaccine or antibiotic to fight it. By manipulating this target, they hope to either reduce the severity of these infections or clear them up faster.
They discovered a peptide secreted by the bacteria that signals its neighbors to produce a toxin called streptococcal pyrogenic exotoxin B (SpeB). The production of SpeB is critical for the development of necrotizing fasciitis, better known as flesh-eating disease. Blocking production of that toxin will be crucial for disease prevention and treatment.
"Researchers have known for more than 100 years that Group A strep uses the toxin SpeB and that it is crucial to disease development," Kumaraswami said. "We did not know, however, what signals the timely production of SpeB by Group A streptococcus. Now that we have discovered how Group A strep bacteria communicate with each other to coordinate the production of this toxin, we can target the signaling pathway for vaccine and antimicrobial development."
Kumaraswami says that bacteria talking to each other and producing toxins is not that new. Their communication codes have been characterized for a long time, so researchers know a lot of the classic features in these signals. What's different in what his team discovered is the nature of the language. The Group A streptococcus communication signal they found lacks a majority of those classic hallmarks.
"Typically, the signal is quite long and has a number of characteristic features," Kumaraswami said. "The signal we found is compact and doesn't have many of what we traditionally see in other bacterial peptides, which is probably what contributed to the difficulties in finding it for such a long time. There could be similar atypical signals in other bacteria that have been overlooked, as well, so we believe the discovery of this peptide will likely facilitate discovering additional bacterial peptide signals in other pathogens."
Moving forward, there are several different avenues researchers could take in targeting this peptide signal for either antibiotic or vaccine development. They can develop antibodies to target it or a competing peptide to jam the communication path, which would allow them to block toxin production and reduce disease severity. The second approach involves triggering the toxin production at the early stage where the toxin level would be minimal. Then, the host's immune response would be triggered and clear the bacterial infection much earlier.
This article has been republished from materials provided by Houston Methodist. Note: material may have been edited for length and content. For further information, please contact the cited source.
Do, H., Makthal, N., VanderWal, A. R., Rettel, M., Savitski, M. M., Peschek, N., . . . Kumaraswami, M. (2017). Leaderless secreted peptide signaling molecule alters global gene expression and increases virulence of a human bacterial pathogen. Proceedings of the National Academy of Sciences. doi:10.1073/pnas.1705972114
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by NovartisNews
The Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced today that Novartis will have access to commercially develop their therapeutic, biomaterial-based, cancer vaccine technology that promotes anti-cancer immunity.READ MORE
Antimicrobial Found in Toiletries Could be Used Against MalariaNews
Triclosan, an antimicrobial compound used in soap, toothpaste, deodorant and many other products, can inhibit target genes in the malaria parasite during two crucial stages of its lifecycle in humans - the hepatic stage.READ MORE
Comments | 0 ADD COMMENT
Microbiome Futures: A Global Translational Roadmap
May 23 - May 23, 2018